GI-128

N/A

Report date: 2026/04/10 20:01:49

Base Information

Drug NameGI-128

Drug Alias NameGI-128

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Programmed death-ligand 1Anti-LILRB

TargetsProgrammed death-ligand 1Leukocyte immunoglobulin-like receptor subfamily B

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGI Innovation Inc

China Registration ClassN/A

Develop Information

Active CompaniesGI Innovation Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A